176 related articles for article (PubMed ID: 28525844)
1. The discovery of novel, potent ERR-alpha inverse agonists for the treatment of triple negative breast cancer.
Du Y; Song L; Zhang L; Ling H; Zhang Y; Chen H; Qi H; Shi X; Li Q
Eur J Med Chem; 2017 Aug; 136():457-467. PubMed ID: 28525844
[TBL] [Abstract][Full Text] [Related]
2. The discovery of a novel series of potential ERRα inverse agonists based on p-nitrobenzenesulfonamide template for triple-negative breast cancer
Gao Z; Wang T; Li R; Du Y; Lv H; Zhang L; Chen H; Shi X; Li Q; Shen J
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):125-134. PubMed ID: 34894977
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of ERRα suppresses epithelial mesenchymal transition of triple negative breast cancer cells by directly targeting fibronectin.
Wu YM; Chen ZJ; Liu H; Wei WD; Lu LL; Yang XL; Liang WT; Liu T; Liu HL; Du J; Wang HS
Oncotarget; 2015 Sep; 6(28):25588-601. PubMed ID: 26160845
[TBL] [Abstract][Full Text] [Related]
4. A novel compound LingH2-10 inhibits the growth of triple negative breast cancer cells in vitro and in vivo as a selective inverse agonist of estrogen-related receptor α.
Ning Y; Chen H; Du Y; Ling H; Zhang L; Chen L; Qi H; Shi X; Li Q
Biomed Pharmacother; 2017 Sep; 93():913-922. PubMed ID: 28715872
[TBL] [Abstract][Full Text] [Related]
5. Inverse agonist of estrogen-related receptor α suppresses the growth of triple negative breast cancer cells through ROS generation and interaction with multiple cell signaling pathways.
Wu YM; Chen ZJ; Jiang GM; Zhang KS; Liu Q; Liang SW; Zhou Y; Huang HB; Du J; Wang HS
Oncotarget; 2016 Mar; 7(11):12568-81. PubMed ID: 26871469
[TBL] [Abstract][Full Text] [Related]
6. Regulation of PPARgamma coactivator 1alpha (PGC-1alpha) signaling by an estrogen-related receptor alpha (ERRalpha) ligand.
Willy PJ; Murray IR; Qian J; Busch BB; Stevens WC; Martin R; Mohan R; Zhou S; Ordentlich P; Wei P; Sapp DW; Horlick RA; Heyman RA; Schulman IG
Proc Natl Acad Sci U S A; 2004 Jun; 101(24):8912-7. PubMed ID: 15184675
[TBL] [Abstract][Full Text] [Related]
7. Antitumor effect of XCT790, an ERRα inverse agonist, on ERα-negative endometrial cancer cells.
Kokabu T; Mori T; Matsushima H; Yoriki K; Kataoka H; Tarumi Y; Kitawaki J
Cell Oncol (Dordr); 2019 Apr; 42(2):223-235. PubMed ID: 30706380
[TBL] [Abstract][Full Text] [Related]
8. Characterization of a selective inverse agonist for estrogen related receptor α as a potential agent for breast cancer.
Zhang L; Liu P; Chen H; Li Q; Chen L; Qi H; Shi X; Du Y
Eur J Pharmacol; 2016 Oct; 789():439-448. PubMed ID: 27498368
[TBL] [Abstract][Full Text] [Related]
9. Novel acetamidothiazole derivatives: synthesis and in vitro anticancer evaluation.
Ali AR; El-Bendary ER; Ghaly MA; Shehata IA
Eur J Med Chem; 2013 Nov; 69():908-19. PubMed ID: 24125851
[TBL] [Abstract][Full Text] [Related]
10. Discovery of a novel dipeptidyl boronic acid proteasome inhibitor for the treatment of multiple myeloma and triple-negative breast cancer.
Lei M; Feng H; Bai E; Zhou H; Wang J; Qin Y; Zhang H; Wang X; Liu Z; Hai O; Liu J; Zhu Y
Org Biomol Chem; 2019 Jan; 17(3):683-691. PubMed ID: 30601533
[TBL] [Abstract][Full Text] [Related]
11. A novel steroidal inhibitor of estrogen-related receptor alpha (ERR alpha).
Duellman SJ; Calaoagan JM; Sato BG; Fine R; Klebansky B; Chao WR; Hobbs P; Collins N; Sambucetti L; Laderoute KR
Biochem Pharmacol; 2010 Sep; 80(6):819-26. PubMed ID: 20513360
[TBL] [Abstract][Full Text] [Related]
12. Pyranoxanthones: Synthesis, growth inhibitory activity on human tumor cell lines and determination of their lipophilicity in two membrane models.
Azevedo CM; Afonso CM; Soares JX; Reis S; Sousa D; Lima RT; Vasconcelos MH; Pedro M; Barbosa J; Gales L; Pinto MM
Eur J Med Chem; 2013 Nov; 69():798-816. PubMed ID: 24113365
[TBL] [Abstract][Full Text] [Related]
13. Identification of a selective inverse agonist for the orphan nuclear receptor estrogen-related receptor alpha.
Busch BB; Stevens WC; Martin R; Ordentlich P; Zhou S; Sapp DW; Horlick RA; Mohan R
J Med Chem; 2004 Nov; 47(23):5593-6. PubMed ID: 15509154
[TBL] [Abstract][Full Text] [Related]
14. Estrogen related receptor α (ERRα) a promising target for the therapy of adrenocortical carcinoma (ACC).
Casaburi I; Avena P; De Luca A; Chimento A; Sirianni R; Malivindi R; Rago V; Fiorillo M; Domanico F; Campana C; Cappello AR; Sotgia F; Lisanti MP; Pezzi V
Oncotarget; 2015 Sep; 6(28):25135-48. PubMed ID: 26312764
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of estrogen-related receptor alpha inhibits human cutaneous squamous cell carcinoma cell proliferation and migration by regulating EMT via fibronectin and STAT3 signaling pathways.
Chen H; Pan J; Zhang L; Chen L; Qi H; Zhong M; Shi X; Du J; Li Q
Eur J Pharmacol; 2018 Apr; 825():133-142. PubMed ID: 29476880
[TBL] [Abstract][Full Text] [Related]
16. Estrogen-related receptor-alpha antagonist inhibits both estrogen receptor-positive and estrogen receptor-negative breast tumor growth in mouse xenografts.
Chisamore MJ; Wilkinson HA; Flores O; Chen JD
Mol Cancer Ther; 2009 Mar; 8(3):672-81. PubMed ID: 19276159
[TBL] [Abstract][Full Text] [Related]
17. Development of Novel Cell Lines for High-Throughput Screening to Detect Estrogen-Related Receptor Alpha Modulators.
Teng CT; Hsieh JH; Zhao J; Huang R; Xia M; Martin N; Gao X; Dixon D; Auerbach SS; Witt KL; Merrick BA
SLAS Discov; 2017 Jul; 22(6):720-731. PubMed ID: 28346099
[TBL] [Abstract][Full Text] [Related]
18. Advances in Medicinal Chemistry of Estrogen-related Receptor Alpha (ERRα) Inverse Agonists.
Zhang H; Du Y; Zheng Y; Lv H; Yan Z; Dong N; Zhu Y; Shen J
Curr Top Med Chem; 2023; 23(20):1952-1963. PubMed ID: 37190810
[TBL] [Abstract][Full Text] [Related]
19. Discovery of derivatives of 6(7)-amino-3-phenylquinoxaline-2-carbonitrile 1,4-dioxides: novel, hypoxia-selective HIF-1α inhibitors with strong antiestrogenic potency.
Buravchenko GI; Scherbakov AM; Dezhenkova LG; Bykov EE; Solovieva SE; Korlukov AA; Sorokin DV; Monzote Fidalgo L; Shchekotikhin AE
Bioorg Chem; 2020 Nov; 104():104324. PubMed ID: 33142432
[TBL] [Abstract][Full Text] [Related]
20. Design and optimization of hybrid of 2,4-diaminopyrimidine and arylthiazole scaffold as anticancer cell proliferation and migration agents.
Zhou W; Huang A; Zhang Y; Lin Q; Guo W; You Z; Yi Z; Liu M; Chen Y
Eur J Med Chem; 2015; 96():269-80. PubMed ID: 25899332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
